Patent intelligence · CA
CA 3152006
TROPOELASTINE DESTINEE A ETRE UTILISEE DANS LE TRAITEMENT DE LA CICATRISATION DE L'ACNE
TROPOELASTINE DESTINEE A ETRE UTILISEE DANS LE TRAITEMENT DE LA CICATRISATION DE L'ACNE
Patent details — CA 3152006
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Mar 4, 2021
- Expiration
- Feb 27, 2041
- Applicant
- ALLERGAN PHARMACEUTICALS INT LTD [IE]
- CPC classes
- A61K 38/ 17 A I, A61K 38/ 39 A I, A61K/31728, A61K/3839
Quick answer
CA 3152006 (TROPOELASTINE DESTINEE A ETRE UTILISEE DANS LE TRAITEMENT DE LA CICATRISATION DE L'ACNE) is held by ALLERGAN PHARMACEUTICALS INT LTD [IE]. Status: granted. Granted Mar 4, 2021. Expires Feb 27, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ALLERGAN PHARMACEUTICALS INT LTD [IE]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 38/ 17 A I, A61K 38/ 39 A I, A61K/31728, A61K/3839, A61K/90014, A61K/90019
More from ALLERGAN PHARMACEUTICALS INT LTD [IE]
Related pharmaceutical patents in our USPTO index.
-
US 12383545
TREATMENT OF MIGRAINE
granted -
US 2025064788
TREATMENT OF MIGRAINE
granted -
US 2024180883
TREATMENT OF MIGRAINE
granted -
WO 2024081718
ANTAGONISTE DU RÉCEPTEUR CGRP POUR LE TRAITEMENT DE LA MIGRAINE
granted -
CA 3244873
TRAITEMENT PRÉVENTIF DE LA MIGRAINE
granted -
WO 2023077094
TRAITEMENT D'UN TROUBLE DÉPRESSIF MAJEUR
granted -
US 2023130736
METHODS OF TREATING MIGRAINE
granted -
US 2022380379
PHARMACEUTICAL COMPOUNDS
granted
Frequently asked questions
What is US patent 3152006?
CA 3152006 (TROPOELASTINE DESTINEE A ETRE UTILISEE DANS LE TRAITEMENT DE LA CICATRISATION DE L'ACNE) is held by ALLERGAN PHARMACEUTICALS INT LTD [IE]. Status: granted. Granted Mar 4, 2021. Expires Feb 27, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 3152006?
ALLERGAN PHARMACEUTICALS INT LTD [IE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 3152006 expire?
Our index shows an expiration date of Feb 27, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.